Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MG-ZG122 in Healthy Chinese Adults
NCT05659927Phase 1Active, not recruiting
- Sponsor
- Hunan Mabgeek Biotechnology
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MG-ZG122 in asthma (4 cohorts), sponsored by Hunan Mabgeek Biotechnology. Primary endpoint: Tolerability and Safety Analysis at 127 days. Started Feb 2023; status: active, not recruiting.
02
Drugs
MG-ZG122
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05659927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659927.